Chronic Myeloid Leukemia (CML)

	08/17/2009	Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML
	08/17/2009	How Can We Clarify Treatment Approaches in High-Risk CML?
	08/17/2009	How Can We Improve Treatment & Outcome in Blast-Crisis CML?
	11/26/2008	Maximizing Outcomes in CML Throughout the Treatment Continuum
	11/26/2008	Long-Term Management of a Patient With Newly Diagnosed, Chronic-Phase CML
	11/26/2008	Choosing Appropriate Second-Line Therapy for a Patient With Progressive/Treatment-Resistant CML
	09/12/2008	Exploring Epigenetic Targets in Solid Tumors and Hematologic Malignancies
	09/12/2008	Understanding Targets of Epigenetic Therapy in Cancer
	09/12/2008	Interpreting Recent Data on HDAC Inhibitors in the Management of Hematologic Malignancies & Solid Tumors
	09/12/2008	Assessing the Role of HDAC Inhibitors in Hematologic Malignancies: Spotlight on Leukemia and MDS
	07/28/2008	Understanding Treatment-Resistant Chronic Myeloid Leukemia
	07/28/2008	Treatment Resistance in Chronic Myeloid Leukemia (CML): What Role Do Point Mutations Play?
	07/28/2008	Monitoring of Patients With Chronic Myeloid Leukemia (CML): Which Tests to Use and When?
	07/28/2008	Looking Into the Future of CML: Individualized Therapy and Strategies to Overcome Cross-Resistance to Approved TKIs
	04/10/2008	New Data on Targeted Agents in CML: Implications for Front-Line and Post-Imatinib Therapy
	04/10/2008	Second-Generation TKIs: A Second Chance for Patients With Imatinib-Resistant/Intolerant CML
	04/10/2008	Matters of Mutation: Polymorphisms Predict Response Among Patients With Imatinib-Resistant CML
	04/10/2008	ASH 2007 Update: How Do Emerging Agents Place in the Management of CML?
	02/14/2008	CML and Ph+ ALL: Tyrosine Kinase Inhibitors Improve Outcomes But Resistance Remains a Concern
	02/14/2008	Novel Targeted Agents Expand Options for Patients Resistant to First-Line CML Therapy
	02/14/2008	Targeted Agents Showing Promise in Imatinib-Resistant Ph+ ALL
	01/31/2008	Understanding Resistance to Imatinib in Chronic Myelogenous Leukaemia
	01/31/2008	Resistance Is Futile: How New Tyrosine Kinase Inhibitors Extend Treatment Options in Chronic Myeloid Leukaemia
	01/31/2008	Strategies to Improve the Use of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukaemia